Doctor of Pharmacy by Gross, Mary Elizabeth
PENETRATION OF CEFOPERAZONE INTO THE VENTRICULAR 
FLUID IN PATIENTS WITH NON-INFLAMED MENINGES 
by 
Mary Elizabeth Gross 
A project submitted to the faculty of the 
University of Utah in partial fulfillment of the requirements 
for the degree of 
Doctor of Pharmacy 
College of Pharmacy 
University of Utah 
June 1982 
UNIVERSITY OF UTAH COLLEGE OF PHARMACY 
FINAL READING APPROVAL 
TO THE DOCTOR OF PHARMACY COMMITTEE OF THE UNIVERSITY OF UTAH COLLEGE OF PHARMACY 
I have read the clinical research project of Mary Elizabeth Gross in its 
final form and have found that 1) its format, citations, and bibliographic 
style are consistent and acceptable; 2) its illustrative materials including 
figures, tables and charts are in place; and 3) the final manuscript is satisfac-
tory to the Supervisory Committee and is ready for submission to the Doctor of 
Pharmacy Committee. 
Appro ' " r the Department of Pharmacy Practice 
Chairman 
Approved for the Doctor of Pharmacy Committee 
Chairpffin, Doctor of Pharmacy Committee 
UNIVERSITY OF UTAH COLLEGE OF PHARMACY 
SUPERVISORY COMMITTEE APPROVAL 
of a clinical research project report submitted by 
Mary Elizabeth Gross 
We, the undersigned, have read this clinical research project report 
and have found it to be of satisfactory quality for a Doctor of Pharmacy 
Degree. 
Bete > upervisory Committee 
Date 
%, /9  ft-
yte 
U ^ Z / f / 2 -
• Is. A /1 
Member, Supervisory Committee 
/ 
Membfer, Supervisory Committee 
•Q X « vO _ 
Men/ber, Supervisory Corfimitftee 
ACKNOWLEDGEMENTS 
I would like to express my sincere thanks and appreciation to 
the members of my Supervisory Committee: Dr. Kelly Mutchie, Dr. Jean 
Nappi, Dr. John Bosso, Dr. James Overall, and Dr. Marion Walker, for 
the time, patience and guidance they have demonstrated in evaluating 
and writing this research paper. 
To my mother, my father, and my grandparents, I would like to 
extend a very special thank you, for their continued support and 
understanding of my goals and expectations. 
To Jim, a very special thank you for his patience, support, 
understanding, and love throughout the past two years. 
TABLE OF CONTENTS 
LIST OF TABLES v 
INTRODUCTION 1 
OBJECTIVES 5 
MATERIALS AND METHODS 5 
Subject Selection 5 
Exclusion Criteria 6 
Study Design 6 







LITERATURE CITED 30 
CURRICULUM VITAE 34 
LIST OF TABLES 
Patient Characteristics 
Concentration of Cefoperazone in Serum and 
Ventricular Fluid, Group A 
Concentration of Cefoperazone in Serum and 
Ventricular Fluid, Group B 
Ventricular Fluid Data 
Pre and Post Cefoperazone Subject Monitoring 
Parameters 
Pre and Post Cefoperazone Complete Blood Count 
Results 
Pre and Post Cefoperazone Laboratory Results . . 
Pre and Post Cefoperazone Urinalysis 
Susceptibility of Clinical Isolates to Ampicillin, 
Methicillin, Nafcillin, and Trimethoprim-
Sulfamethoxazole 
Susceptibility of Clinical Isolates to 
Cefoperazone 
INTRODUCTION 
Hydrocephalus is characterized by an abnormal accumulation of 
fluid within the cranial vault. This results from an increased pres-
sure gradient between the intraventricular fluid and the brain due to 
the inadequate removal of this fluid by the lymphatic, circulatory, 
and central nervous systems. Possible etiologies of this disorder 
include: (1) congenital malformation; (2) excess formation of cere-
bral spinal fluid by the choroid plexus, which may or may not be 
accompanied by abnormal absorption of the fluid into the vascular 
system; (3) cysts and neoplasms involving the brain; (4) infections 
within the central nervous system; and (5) trauma. Clinical signs 
and symptoms of hydrocephalus include an increase in the intracranial 
pressure, enlargement of the cranium, headaches, vomiting, confusion 
and lethargy. 
Intracranial pressure is regulated by the rate of formation and 
the resistance of the arachnoid villi to absorb the fluid. Normal 
cerebral spinal fluid pressure is between 70 to 180 mrr^O. With 
hydrocephalus, this pressure may increase to 400 to 600 mn^O. If 
this condition is left untreated, the resultant increase in fluid 
pressure may lead to atrophy of the brain, mental deterioration or 
o 
convulsions. Surgical placement of ventriculo-peritoneal (VP) shunts 
are used in patients with hydrocephalus to relieve the elevated intra-
cranial pressure, by providing a route for removal of the excess fluid. 
A major complicating factor which contributes to the morbidity 
same study, it appeared that patients who received prophylactic anti-
biotic therapy directed at staphylococci had a lower incidence of 
infection. The results of this and other similar studies have led to 
the use of antimicrobial prophylaxis perioperatively during shunt 
O Q 1 p 1 £ 
placement procedures. ' " Ampicillin, methicillin, nafcillin 
and trimethoprim-sulfamethoxazole have been used in this institution.* 
Prevention of infection should lead to decreased hospitalizations, 
decreased number of shunt revisions, and a decrease in the overall 
morbidity and associated mortality. It is therefore desireable to 
treat the patient prophylactically with an antibiotic that will be 
active against the primary organisms involved. 
Cefoperazone (Cefobid,® Pfizer Pharmaceuticals), which is 
structurally related to cefamandole and piperacillin (Figure 1), is a 
semisynthetic cephalosporin for parenteral use. Like other beta-
lactam antibiotics, cefoperazone inhibits cell wall synthesis by 
inhibiting the transpeptidase enzyme, which prevents the splitting of 
the peptide bond between the two terminal D-alanine residues of each 
17 
polypeptide side chain. In vitro, cefoperazone is relatively resis-
tant to beta-lactamase induced hydrolysis. In vitro and in vivo data 
have shown this agent to be active against both gram positive and 
gram negative organisms, including staphylococcus sp., Escherichia 
coli, pseudomonas sp., klebsiella sp., proteus sp., and Haemophilus 
influenzae.18,19 
Cefoperazone elimination follows a two-compartment model, with a 
20 21 
rapid distribution phase (6.6 ± 3.1 minutes). ' The elimination 
half-life has been reported to be 1.6 to 2.05 hours in healthy subjects 
•Primary Children's Medical Center, Salt Lake City, Utah. 
18 after intravenous administration. High pressure liquid chromato-
22 
graphy studies have detected degradation products of cefoperazone. 
Activity of these metabolites has not been reported to date. The 
apparent volume of distribution of cefoperazone in healthy subjects 
has been reported as 9.4 to 14.5 liters in the adult, and 0.5 liters 
18 21 23 
per kilogram in the newborn infant. ' ' Cefoperazone has been 
found to have a protein binding capacity of approximately 90 percent 
to human albumin.18'23'24 
Penetration into the cerebral spinal fluid (CSF) has been reported 
in rabbits with inflamed meninges, following a single dose infusion of 
cefoperazone at 25 mg/kg. The CSF levels were found to be between 
25 
4.2 and 8.2 percent of the concurrent serum concentration. This 
agent penetrates into the CSF in pediatric patients with bacterial 
meningitis and Anderson et al. have reported CSF concentrations of 
cefoperazone ranging between 1.8 to 3.7 mcg/ml in newborn infants 
(range 4 to 26 days) with noninflamed meninges.* 
Cefoperazone generally has been well tolerated following paren-
teral administration. Adverse effects in 21 of 756 patients treated 
26 
with cefoperazone in clinical trials in Japan have been reported. 
The most commonly reported side effects included rash, diarrhea, 
fever, dizziness, chills, headaches, and vascular pain following intra-
venous injection. Abnormal laboratory results were seen in an addi-
tional 21 patients. These included transient elevations of serum 
transaminases, alkaline phosphatase, and eosinophilia. 
Cefoperazone, with its broad spectrum of activity, apparent 
*Donald Hilligos, Pharm.D., Assistant Professor of Clinical Pharmacy 
West Virginia University, personal communication, May 1982. 
ability to penetrate into the central nervous system, and low incidence 
of side effects, may represent an alternative to the present antibiotic 
regimen used for prophylaxis in VP shunt procedures. 
OBJECTIVES 
The objectives of this study were to determine simultaneous serum 
and ventricular fluid levels and side effects of cefoperazone in child-
ren with non-inflamed meninges requiring perioperative antibiotic pro-
phylaxis for placement or revision of a VP shunt. The ventricular 
fluid levels obtained were then compared to the in vitro concentra-
tions required to inhibit bacterial growth of the most common organ-
isms associated with VP shunt infections. 
MATERIALS AND METHODS 
Subject Selection 
Five subjects requiring perioperative antibiotic prophylaxis for 
placement, or revision, of a VP shunt were selected for the study. 
Three of the subjects underwent surgery for placement of the VP shunt 
for the first time. Patient characteristics are listed in Table 1. 
There were three males and two females with an average age of 7.5 
months (range 6 days to 30 months). Subject number one was reentered 
into the study three months after the initial placement of the VP 
shunt for revision of the shunt, as subject number four. Suitability 
to participate in the study was determined by medical history and 
physical examination performed by the physician co-investigator. 
Objective evaluation was completed by a battery of laboratory tests 
(complete blood count with differential and reticulocytes, prothrombin 
time, liver function tests, serum creatinine, and complete urinalysis). 
Exclusion Criteria 
The following exclusion criteria were used: (1) subjects with 
evidence of renal disease indicated by a serum creatinine greater than 
1.5 mg/dl; (2) subjects with evidence of hepatic disease indicated by 
a serum glutamic oxaloacetic transaminase greater than 50 IU/L, a 
serum glutamic pyruvic transaminase greater than 50 IU/L, or a gamma 
glutamyl transpeptidase greater than normal as determined by the sub-
ject's age; (3) subjects with a documented history of an allergic 
reaction to cephalosporin antibiotics; (4) subjects with a history 
of an anaphylactoid reaction to penicillin antibiotics; (5) subjects 
less than 38 weeks of gestational age; (6) any subject within 14 days 
of the initial diagnosis of inflamed meninges; and (7) subjects' 
parents or guardians who declined to sign the study consent form. 
Study Design 
The study was an open, noncomparative trial of a single dose of 
cefoperazone, which was administered in conjunction with the antibio-
tics routinely administered (ampicillin, methicillin, or trimethoprim-
sulfamethxazole) for perioperative prophylaxis of VP shunt placement 
or revision. Subjects were divided consecutively into two groups 
designated A and B. Group A participants received 50 mg/kg of cefoper-
azone, while subjects in group B received 100 mg/kg. This change in 
dosage was due to clinical data received by the sponsor* indicating 
the safety and efficacy of the higher dose. Baseline laboratory values 
were obtained no less than 48 hours prior to administration of the 
agent. Blood pressure, heart rate, temperature, respiratory rate, 
*Pfizer Pharmaceuticals, New York, New York. 
the presence or absence of lethargy and irritability, and the appear-
ance of the injection site were recorded prior to the infusion of cef-
operazone. A two milliliter blood sample was obtained prior to the 
administration of the agent. This sample served as a blank. The sam-
ple was centrifuged at 5000 rpm for five minutes to separate the 
plasma from the cells. The plasma was decanted into a glass tube and 
promptly frozen at -70° C. Each subject then received one dose of 
cefoperazone (50 mg/kg or 100 mg/kg), which was infused over one to 
two minutes prior to the subject being called to the operating room, 
with one exception. Neither the resident nor the phlebotomist were 
able to start the I.V. prior to subject number five being transported 
to the operating room. Consequently, the cefoperazone was administered 
in the operating room by the anesthesiologist. A four milliliter 
sample of the ventricular fluid sample was obtained at the time of 
shunt placement. Half of this sample was sent for gram stain, culture, 
cell count, and glucose and protein determination. In addition, a two 
milliliter blood sample was obtained by the physician at a site other 
than the original cefoperazone injection site at a time as near to the 
drawing of the ventricular fluid as was feasible during the surgical 
procedure. The blood sample was taken to the laboratory and centri-
fuged at 5000 rpm for five minutes to separate the plasma from the 
cells. The plasma was then decanted into a glass tube. Both the 
ventricular fluid and serum samples were then promptly frozen at 
-70° C. The samples were analyzed within four months of collection. 
Samples remain stable for a minimum of one month if thawing is avoided.* 
*Marvin Meyer, Ph.D., Professor, Assistant Dean, College of Medicine, 
University of Tennessee, personal communication, May 1982. 
Subjects were monitored for adverse effects for 24 to 48 hours after 
the administration of cefoperazone. The time of onset, duration, and 
severity of side effects were recorded. Follow-up laboratory studies 
were performed between 12 to 24 hours after the administration of 
cefoperazone. 
Cefoperazone Assay 
The cefoperazone assay was performed by Dr. Marvin Meyer at the 
University of Tennessee. A gradient high pressure liquid chromato-
graphy (HPLC) procedure was used for the determination of the amount 
of cefoperazone in human serum and CSF. This assay adequately separ-
ated cefoperazone from other antibiotics and cefoperazone degradation 
products. The sensitivity of the assay for the serum was less than 
five mcg/ml and less than one mcg/ml for the CSF. The coefficient of 
variation was less than 5.5 percent. 
RESULTS 
In group A subjects there were no concomitant serum samples avail-
able for analysis (Table 2). In two subjects (number one and three), 
the CSF levels were 0.2 mcg/ml and 0 mcg/ml at 120 and 185 minutes 
after the dose respectively. The mean time between drawing the CSF 
and serum samples for the subjects in group A was 11 minutes (range 7 
to 25 minutes). 
Ventricular fluid and serum samples were analyzed for the three 
subjects in group B (Table 3). Cefoperazone was detected in the CSF 
of two subjects (four and six). The CSF concentrations were 7.5 mcg/ml 
and 3.2 mcg/ml, respectively. The percentage of cefoperazone in the 
CSF compared to the serum were 2.35 percent and 1.64 percent, 
respectively. No cefoperazone was detected in the CSF in subject five, 
while the concurrent serum concentration was 247.7 mcg/ml. The mean 
time between drawing of the CSF and serum samples for group B was 15.3 
minutes (range 10 to 23 minutes). 
All gram stains and cultures of the CSF for all subjects were 
negative after 72 hours. The CSF cell counts and glucose and protein 
levels did not suggest the presence of inflamed meninges in all but 
subjects four and six (Table 4). Monitoring parameters were not altered 
after the administration of a single dose of cefoperazone (Table 5). 
Subject one experienced one episode of diarrhea 24 hours after the dose 
was administered. This same subject had experienced diarrhea prior to 
the infusion of cefoperazone. Subject two complained of a headache, 
which required treatment with 60 mg of acetaminophen, nine hours after 
receiving the cefoperazone. The staff could not associate the headache 
as an adverse effect versus pain at the site of incision. The complete 
blood count was normal in all subjects, except for subject six who 
demonstrated a rise in eosinophils from 3 to 15 percent (Table 6). 
Subjects one, three, five and six demonstrated a mean reduction in 
reticulocytes of 59.7 percent (range 47.8 to 71.4%), a mean decline in 
red blood cells of 18.4 percent (range 9.5 to 31.6%), and a mean reduc-
tion in hematocrit of 20.9 percent. The reticulocyte counts remained 
27 
within the normal range for those subjects as determined by their age. 
Subject three demonstrated a slight increase in liver function 
tests, though the values remained within the normal range. No changes 
in liver function tests were noted in the remaining subjects (Table 7). 
Urinalysis remained unchanged in all subjects (Table 8). Follow-up 
laboratory tests could not be obtained in subject number two due to 
refusal of the mother to allow the samples to be drawn. 
DISCUSSION 
The samples obtained from group A subjects could not be used in 
the evaluation of the study because the initial assay procedure was 
not sensitive enough to measure the small quantity of cefoperazone in 
the CSF. In the process of concentrating the samples, the drug was 
degraded, invalidating the data obtained. Cefoperazone was detected 
in the CSF sample of subject one after at least one thawing, suggest-
ing that the penetration into the CSF does occur. Thawing has been 
shown by Meyer to result in approximately 50 percent degradation 
of the sample.* These subjects (group A) were retained in the study to 
note any adverse effects incurred or alteration of laboratory tests 
demonstrated. 
Penetration of the cefoperazone into the CSF was noted in two of 
the three subjects in group B. Cefoperazone was not detected in the 
CSF prior to 40 minutes after the administration of the agent. Inter-
patient variability of both serum and CSF levels was demonstrated. 
This variability is consistent with the data reported in three new-
born infants with non-inflamed meninges, in which the peak serum 
levels ranged from 133 to 214 mcg/ml. The CSF levels of cefoperazone 
22 
ranged from less than one mcg/ml to nine mcg/ml. The delay in 
penetration suggested by the group B subjects may be related to the 
extensive protein binding of cefoperazone. The concentration of cef-
operazone in the CSF may have been altered by the enlarged ventricles 
detected by computer axial tomography (CAT) scan in the three subjects 
*Marvin Meyer, Ph.D., Professor, Assistant Dean College of Medicine, 
University of Tennessee, personal communication, May 1982. 
in group B at the time of surgery. Hydrocephalic patients often have 
enlarged ventricles, which may alter the volume of distribution of the 
antibiotic administered. McCullough et al. demonstrated an inverse 
relationship between ventricle size and the concentration of nafcillin 
oo 
in the CSF. The increased protein and white blood cells in the ven-
tricular fluid in subjects four and six suggest an alteration of the 
meninges, which may have been seen due to the penetration of cefopera-
zone into the CSF in these two subjects. In subject four, the original 
shunt had been fused to the choroid plexus. Upon removal of the shunt, 
there may have been an influx of serum accounting for higher levels of 
glucose, blood cells, and cefoperazone. Subject six underwent shunt 
placement 14 days prior to the procedure in which the cefoperazone was 
administered. The CSF protein count has been increased in subjects who 
have undergone recent neurosurgical procedures. In both subjects, the 
meninges may have been altered, despite negative cultures and gram 
stains, which would influence the penetration of cefoperazone into the 
CSF. 
Diffusion of antibiotics into the CSF has been considered desir-
able for antimicrobial prophylaxis against infection in ventriculo-
peritoneal shunt procedures. Presently, ampicillin, methicillin, 
nafcillin, and trimethoprim-sulfamethoxazole are utilized in this 
institution. Penetration into the CSF for each of these agents is 
limited in the absence of inflamed meninges. Other factors which 
influence the ability of antibiotics to penetrate into the CSF include 
lipid solubility, molecular size and structure, and degree of ioniza-
31 
tion at physiological pH, and active transport mechanisms. The 
mean CSF concentration of ampicillin was determined in 44 patients in 
10 days after the initial diagnosis and initiation of treatment for 
29 
bacterial meningitis. The concentration of ampicillin was noted to 
decrease through the course of therapy, as the inflammation subsided. 
The mean concentration of ampicillin in the CSF at day 10 was 0.8 
mcg/ml (range less than 0.03 to 5.9 mcg/ml). This study also demon-
strated no correlation between the clinical outcome of each patient 
and the antibiotic level achieved in the CSF. Peak CSF concentrations 
of methicillin have been determined in five patients with non-inflamed 
30 
meninges to range between 0 to 0.69 mcg/ml. In bacterial meningitis, 
the maximum concentration of methicillin detected has been 2.8 
30 31 
mcg/ml. ' The mean CSF concentration of nafcillin has been determined 
3° 
in eight patients with no evidence of inflamed meninges. "" The mean 
peak concentration was 0.12 mcg/ml (range 0.03 to 0.17 mcg/ml). This peak 
occurred two hours after the end of the infusion. The penetration of 
trimethoprim (TMP) and sulfamethoxazle (SMX) were determined on four 
33 
patients with inflamed meninges. The mean concentration of TMP 
was 1 mcg/ml (range 0.7 to 1.4 mcg/ml) and that of SMX was 4.5 mg/dl 
(range 1.7 to 8.2 mg/dl). It appears that the concentration of the 
antibiotic in the CSF is often less than the minimum inhibitory con-
29 31 34 35 
centration for the pathogen involved (Table 9). ' ' ' However, 
these agents have been utilized successfully, both in the management 
of bacterial meningitis and as prophylactic antimicrobials in shunt 
procedures. 8' 9' 1 4 - 1 6' 2 9" 3 1' 3 3' 3 6' 3 7 In this study, the concentration 
of cefoperazone in the CSF in one subject appears to be adequate to 
achieve the minimum inhibitory concentration for 90 percent of the iso-
lates for the common VP shunt pathogens, if the meninges were not 
38 
altered (Table 10). Further studies will be necessary to determine 
the effective concentration of cefoperazone in the CSF to prevent VP 
shunt infections. 
Adverse effects were minimal in this study population. The 
18 
eosinophilia reported in one subject is not uncommon. The mechanism 
is not understood at this time. The mild increase in liver function 
tests as noted in one subject has also been reported. Previous 
studies have indicated that this alteration is usually transient in 
18 
nature. This subject was not monitored beyond 24 hours, as his 
values remained within the normal limits. 
A decrease in reticulocytes, which remained within the normal 
limits, was observed in four subjects. This was associated with a con-
current decrease in hematocrit and red blood cell count. Further 
multi-dose studies will be needed to determine the clinical signifi-
cance of this adverse effect. 
CONCLUSION 
Cefoperazone is a new semisynthetic cephalosporin with a broad 
spectrum of antimicrobial activity. This agent appears to penetrate 
into the CSF in children with non-inflamed meninges and may be an 
alternative to the present antibiotic regimens used in patients requir-
ing perioperative prophylaxis for shunt placement or revision. Further 
double-blind trials will be necessary to evaluate the efficacy of 
cefoperazone as a prophylactic agent in VP shunt procedures. Additional 
studies to address the severity of the decreased reticulocyte count 
demonstrated in four subjects in this study will be necessary. 





TABLE 1. PATIENT CHARACTERISTICS. 
Patient 
Age at Time 








1 6 days Male 51 3.62 Hydrocephalus post myelomeningocele 
repair 
No 
2 30 months Female 87 11.80 Dislodged VP shunt Yes 
3 6.5 months Male 67 5.27 Hydrocephalus at birth No 
Group B 
4 3 months Male 64 6.68 Obstructed VP shunt Yes 
5 10 days Female 50 2.69 Hydrocephalus post myelomeningocele 
repair 
No 
6 5 months Male 48 2.81 Hydrocephalus - porencephalic cyst Yes 
VP - ventriculo-peritoneal 
TABLE 2. CONCENTRATION OF CEFOPERAZONE IN SERUM AND VENTRICULAR FLUID, GROUP A. 
Patient 1 2 3 
Pre-dose serum concentration 
(mcg/ml) a - -
Ventricular fluid concentration 
(mcg/ml) 0.2 - 0.0 
Concomitant serum concentration 
(mcg/ml) - - -
Time of sample after administration 
(minutes) 120 - 185 
a - no sample available for evaluation 
TABLE 3. CONCENTRATION OF CEFOPERAZONE IN SERUM AND VENTRICULAR FLUID, GROUP B. 
Patient 4 5 6 
Pre-dose serum concentration 
(mcg/ml) 0.0 0.0 0.0 
Ventricular fluid concentration 
(mcg/ml) 7.5 0.0 3.2 
Concomitant serum concentration 
(mcg/ml) 319.5 247.2 195.7 
Time of sample after administration 
(minutes) 120 27 40 
Percent penetration into CSF 2.35 0 1.64 
TABLE 4. VENTRICULAR FLUID DATA. 
Patient 1 2 3 4 5 6 












WBC/MM3 1 0 3 57 1 149 
PMN's (percent) 0 0 0 17a 0 43b 
Lymphocytes (percent) 0 0 0 76 0 38 
Erythrocytes/MM3 247 2,000 704 70,000 1 69 
Other (percent) - - - monos - 3 
eos - 4 
- monos - 19 
Protein (mg/dl) 55 QNS 18 60 46 1,415 
Glucose (mg/dl) 34 85 49 207 92 40 
Ventricular fluid 
gram stain neg. neg. neg. neg. neg. neg. 
Ventricular fluid 
culture NG NG NG NG NG NG 
PMN's - polymorphonuclear leukocytes 
monos - monocytes 
eos - eosinophils 
NEG. - negative 
NG - no growth for 72 hours 
a - 16% neutrophils, 1% bands 
b - 34% neutrophils, 9% bands 
QNS - quantity not sufficient 
si. hazy - slightly hazy 
r\3 
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Pre Post Pre Post Pre Post Pre Post Pre Post 





166 150 142 160 136 140 
16 42 42 48 38 32 
60/P 96/60 102/78 90/68 100/60a 108/P 78/P 65/P 72/P 80/P 92/P 
++ ++ + d 
clear clear 
diarr. diarr. 
AL/AC AL/AC AL/AC AL/AC AL/AC AL/AC 
clear clear clear13 clear clear clear clear clear clear clear 
H. A. - -
a - crying at time of evaluation ax - axial temperature 
b - initial infusion resulted in infiltration due to r - rectal temperature 
the technique of administration clear - without erythema or inflammation 
c - head discomfort diarr. - diarrhea 
d - responded to stimuli lethargically AL/AC - alert and active 
H.A. - headache 
TABLE 6. PRE AND POST CEFOPERAZONE COMPLETE BLOOD COUNT RESULTS. 
Patient 1 2 3 4 5 6 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
Hemoglobin 20.7 13.7 14.1 - b 15.9 14.4 11.7 9.2 14.8 13.5 15.9 11.3 
(g/di) 
Hematocrit 60.8 40.5 43.2 48.2 43.0 35.9 28.0 44.3 40.3 47.0 32.0 
(percent) 
WBC - ? 10.0 14.1 9.4 13.1 13.4 7.3 9.4 15.5 24.1 17.2 18.8 
(xlO /mm ) 
Neutrophils 28 40 27 47 65 9 19 23 62 14 13 
(percent) 
Bands 6 19 1 10 2 0 3 1 2 1 22 
(percent) 
Lymphocytes 44 25 63 27 24 81 77 58 21 71 40 
(percent) 
Monocytes 18 15 7 11 7 8 1 6 10 11 11 
(percent) 
Eosinophi1s 4 1 2 5 2 2 0 11 5 3 15 
(percent) 
Basophils 0 0 0 0 0 0 0 0 0 0 0 
(percent) 
RBC , 6.55 4.48 5.21 - 5.57 4.83 4.29 3.09 3.79 3.43 5.06 4.08 
(xlO /mm ) 
Reticulocytes 
(percent 1.9 0.9 1.1 1.6 0.9 1.5 3.4 1.6 0.9 2.4 1.2 
(xl03/mm3) 124 40 58 83 43 52 105 61 31 121 49 
(percent3) 2.8 0.8 1.4 2.3' 1.2 1.7 3.1 1.7 0.8 3.6 1.2 
39 
a - corrected for hematocrit as determined by the age of the patient 
b - sample not obtained 
Formula for correcting reticulocyte count: (Hct(low normal) - Subject's Hct) X Reticulocyte count (%) 
rv> rv> 
TABLE 7. PRE AND POST CEFOPERAZONE LABORATORY RESULTS. 
Patient 
SGOT (IU) 33 24 24 _c 24 
SGPT (IU) 
ALKP (IU/L) 
12 10 10 - 6 
201 183 159 - 202 
GGPT (IU/L) 65 68 3 - 4 
LDH (IU/L) 519 434 256 - 228 
Total Bilirubin 8.3 5.5 0.7 - 0.7 
(mg/dl) 
Total Protein 5.0 5.2 6.4 - 5.5 
(9/dl) 
Albumin 2.7 2.8 4.1 - 3.7 
(g/di) 
Serum Creatinine 0.4 0.4 0.4 - 0.5 
(mg/dl) 
Prothrombin Time 10.8/ 12.0/ - - 10.0/ 
(seconds)3 11.4 11.0 10.9 
21 20 16 18 16 26 17 
13 15 15 7 8 15 11 
176 178 167 148 131 430 402 
9 20 16 28 27 60 53 
254 214 174 300 290 221 208 
0.7 0.6 0.3 3.7 1.6 0.4 0.3 
6.7 5.3 5.2 4.8 4.6 4.7 4.0 
3.4 3.7 3.2 3.1 2.9 2.9 2.5 
0.4 0.3 0.4 0.5 0.6 0.4 0.3 
11.6/ 11.0/ 10.7/ 11.9/ - - -
11.3 11.3 10.8 11.5 
a - patient/control 
b - during rapid growth phases, higher levels than 
normal may be seen 
c - sample not obtained 
SGOT - serum glutamic oxaloacetic transaminase (5-40) 
SGPT - serum glutamic pyruvic transaminase (5-40) 
LDH - lactic acid dehydrogenase (120-300) 
Serum Creatinine (0.3-1.0) 
Total Protein (6.3-7.5 0-2 months; 4.7-6.7 3-6 
months; 4.8-7.0 7-24 months) 
GGPT - gamma glutamyl transpeptidase 
(<206 0-1 month; <71 2-4 months; 
<37 4-7 months; <22 7 months-10 years) 
Total Bilirubin (0.1-1.4 after month; up to 12.0 
during the first month 
TABLE 8. PRE AND POST CEFOPERAZONE URINALYSIS. 
Patient 1 2 3 
Pre Post Pre Post Pre Post 
Appearance yel/cl - a yel/cl yel/cl 
pH 5.0 - 5.5 5.5 
Specific gravity 1.002 - 1.002 1.005 
Glucose 0 0 0 
Acetone 0 0 0 
Protein 0 0 0 
Casts/HPF 0 0 rare 
RBC/HPF 0 0 rare 
WBC/HPF rare occs. rare 
Epithelial 
eel 1s/HPF 
rare 0 0 
Bacteria/HPF 0 0 rare 
Urobinogen wnl wnl wnl 
wnl - within normal limits 
occs. - occasional 
yel - yellow 
cl - clear 
HPF - high power field 
a - sample not obtained 
str - straw 
4 5 
Pre Post Pre 
str/cl yel/cl yel/cl 
7.0 7.0 7.0 
1.003 1.003 1.002 
0 0 0 
0 0 0 
0 0 0 
0 0 0 
0 0 0 
occs. 0 0 
occs. 0 0 
0 0 0 
0.1 0 wnl 
6 
Post Pre Post 
yel/cl str/cl yel/cl 
6 . 0 6 . 0 6 . 0 
1.006 1.008 1.004 
0 0 0 
0 0 0 
0 0 0 
0 0 0 
0 6 0 
0 4-6 0 
0 2-4 0 
0 0 0 
wnl 0.1 wnl 
TABLE 9. SUSCEPTIBILITY OF CLINICAL ISOLATES TO AMPICILLIN, METHICILLIN, NAFCILLIN, AND 
TRIMETHOPRIM-SULFAMETHOXAZOLE.34,35 
Minimum Inhibitory Concentration (mcg/ml) 
Ampicillin Methici11 in Nafcillin Trimethoprim-Sulfamethoxazole 
Staphylococcus aureus 1.6 1.6 0.4 0.4 
Staphylococcus epidermidis 0.1 1.6 0.2 0.4 
Escherichia coli 5.0 - 0.4 
Klebsiella pneumoniae 1.25 - 0.8 
Proteus mirabilis 1.25 - 0.8 
r\-) <ji 
















CONSENT AND AGREEMENT TO PARTICIPATE AS AN 
EXPERIMENTAL SUBJECT IN CLINICAL RESEARCH 
Date: 
Your child will be undergoing a surgical procedure which is 
routinely treated with antibiotics (your child will receive the routine 
antibiotics in addition to the new agent, cefoperazone). Antibiotics 
are used in an effort to prevent infection. Presently two antibiotics 
are used to achieve the desired treatment. New antibiotics are being 
developed all the time; cefoperazone is one of these. However, its 
effectiveness is based on its ability to get into the cerebral spinal 
fluid (CSF). The concentration of the antibiotic can be measured dur-
ing the surgical procedure. This would involve nothing out of the 
ordinary, as serum and cerebral spinal fluid samples are routinely 
drawn for cultures. In our study, we will use one serum and one CSF 
sample. We would like to correlate the amount of drug getting into 
the fluid with the level in the blood at the same time. From this 
information, we will be able to evaluate this antibiotic's use in the 
treatment of cerebral infections. 
To complete our study, we will need one serum and one CSF sample. 
Because of the importance of these two samples in the analysis of the 
antibiotic cefoperazone, we ask your permission to obtain these 
samples for the benefit of your child, and at no cost to you. You may 
withdraw your consent for this study at anytime without prejudice. 
Medical treatment or compensation for physical injury: In the 
event you sustain physical injury resulting from the research project 
in which you are participating, the University of Utah will provide you 
without charge, emergency and temporary medical treatment not otherwise 
covered by insurance. Furthermore, if your injuries are caused by negli-
gent acts or omissions of University employees acting in the course and 
scope of their employment, the University may be liable, subject to 
limitations prescribed by law, for additional medical costs and other 
damages you sustain. If you believe that you have suffered a physical 
injury as a result of participation in this research program, please 
contact the Office of Research Administration, Phone No. 581-6903. 
The above clinical research project in which I have volunteered 
to participate as an experimental subject has been fully explained to 
me, and I understand the purpose of the project and the potential 
benefits to be derived therefrom. I have also had explained to me and 
fully understand the procedures that will be carried out on my person, 
and the potential risks and discomforts that are involved. The pre-
cautions that will be taken to protect my welfare have been explained 
to me, and I understand that all possibility of injury cannot be avoided 
even when these precautions are followed. Nevertheless, I voluntarily 
assume these risks in order to advance medical knowledge. 
I acknowledge that I have had a fair opportunity to ask questions 
about the above procedures. I understand that I am free to withdraw 
my consent and to discontinue participation in the project at any 
time without prejudice. I agree that data from these experiments may 
be used for medical and scientific purposes, including publication, 
with the understanding that my identity will not be revealed unless 
I expressly consent thereto. 
Patient: Signature: 
If patient is a minor or unable to sign, complete the following in 
addition to the above: 
As legal guardian of the above-named patient, I verify that I under-
stand the nature of these procedures and that I am legally authorized 
to sign for this patient. 
Patient is a minor , 
(age) Signature of Parent or Guardian 
Patient is unable to sign because: 
Signature of Legal Guardian 
Hospital No.: Witness: 
Responsible Investigator's Signature: 
Protocol No. and Title: 
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